Fundraising Fox
Relmada Therapeutics
NASDAQ: RLMDNew York, US · Founded 2012 · Nevada corporation · 15 known investors
Find your way into Relmada Therapeutics
Sign up to see every warm intro you have to Relmada Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Relmada Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Relmada is a clinical-stage biopharmaceutical company developing therapies including NDV-01, a sustained-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer, and Sepranolone, a candidate targeting compulsive behaviors via GABAA receptor modulation. Its programs address indications such as bladder cancer and Prader-Willi syndrome.
Founders & leadership
ST
Sergio TraversaExecutive
PK
Paul KellyExecutive
EO
Eliseo O. SalinasPresident & Chief Scientific Officer2014–2015Eliseo Salinas is President and Chief Scientific Officer of Relmada Therapeutics, a clinical-stage biopharmaceutical company. He brings over 25 years of experience in biotech and pharmaceutical drug development, with involvement in numerous FDA approvals and clinical development programs.
DB
Douglas BeckChief Financial Officer
CE
Charles EnceChief Accounting and Compliance Officer
CC
Charles CasamentoNamed on SEC filing
Board
SS
Sandesh SethLead Director
SA
Shreeram AgharkarBoard director
NM
Nabil M. YazgiBoard director
Investors · 15
BioAdvancelisted by BioAdvanceConshohocken · $500K – $1.5M
How we know: BioAdvance's portfolio page · Not right? Tell us
BAM ElevatereportedChicago
How we know: allsci.com · Not right? Tell us
BraidwellreportedStamford
How we know: allsci.com · Not right? Tell us
Commodore CapitalreportedNew York
How we know: allsci.com · Not right? Tell us
RA CapitalreportedBoston
How we know: stocktitan.net · Not right? Tell us
Also in the syndicate · 6
Columbia Threadneedle InvestmentsEventide Asset ManagementGreat Point PartnersJanus HendersonSpruce Street CapitalSquadron Capital Management
Funding
SEC filings, press & company announcements$211.1M disclosed across 8 of 10 rounds · 1900–2026
- $160MraisedMar 2026 · 2 sources
Adage Capital Management, Balyasny Asset Management, Braidwell LP, Columbia Threadneedle Investments, Commodore Capital, Eventide Asset Management, Great Point Partners, Janus Henderson, Janus Henderson Investors, Marshall Wace, OrbiMed, RA Capital, Spruce Street Capital, Squadron Capital Management, Venrock, Venrock Healthcare Capital Partners
Source ↗
▶$825.8KraisedOct 2019 · 7 investors · BiotechnologyRule 506(b)
▶$825.8KraisedOct 2019 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Maged ShenoudaDirector
- Ottavio VitoloExecutive Officer
- Paul KellyDirector
- Charles CasamentoDirector
- Chuck EnceExecutive Officer
- Sergio TraversaExecutive Officer, Director
- Offering amount
- $825.8K
- Amount sold
- $825.8K
- Minimum investment
- $10K
- First sale
- Sep 2019
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$8.4MraisedJul 2019 · 116 investors · BiotechnologyRule 506(b)
▶$8.4MraisedJul 2019 · 116 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Charles CasamentoDirector
- Sergio TraversaExecutive Officer, Director
- Ottavio VitoloExecutive Officer
- Paul KellyDirector
- Maged ShenoudaDirector
- Offering amount
- $10M
- Amount sold
- $8.4M
- Minimum investment
- $10K
- Sales commissions
- $688.9K
- Placement agents
- Brookline Capital Markets, A division of Arcadia Securities, LLC, Alexander Capital, LP
- First sale
- Jun 2019
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$3.4MraisedMay 2019 · 43 investors · BiotechnologyRule 506(b)
▶$3.4MraisedMay 2019 · 43 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sergio TraversaExecutive Officer, Director
- Charles CasamentoDirector
- Ottavio VitoloExecutive Officer
- Maged ShenoudaDirector
- Paul KellyDirector
- Offering amount
- $10M
- Amount sold
- $3.4M
- Minimum investment
- $10K
- Sales commissions
- $221.2K
- Placement agents
- Alexander Capital, LP, Brookline Capital Markets, A division of CIM Securities, LLC
- First sale
- May 2019
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$5.8MraisedDec 2018 · 66 investors · BiotechnologyRule 506(b)
▶$5.8MraisedDec 2018 · 66 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Paul KellyDirector
- Ottavio VitoloExecutive Officer
- Sergio TraversaExecutive Officer, Director
- Maged ShenoudaDirector
- Charles CasamentoDirector
- Offering amount
- $10M
- Amount sold
- $5.8M
- Minimum investment
- $10K
- Sales commissions
- $563.9K
- Placement agents
- Alexander Capital, LP
- First sale
- Oct 2018
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$6.9MraisedOct 2017 · 65 investors · BiotechnologyRule 506(b)
▶$6.9MraisedOct 2017 · 65 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sergio TraversaExecutive Officer, Director
- Charles CasamentoDirector
- Paul KellyDirector
- Maged ShenoudaDirector
- Offering amount
- $6.9M
- Amount sold
- $6.9M
- Minimum investment
- $5K
- Sales commissions
- $584.5K
- Placement agents
- Alexander Capital, LP
- First sale
- Sep 2017
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$10.7MraisedJun 2014 · 236 investors · BiotechnologyRule 506(b)
▶$10.7MraisedJun 2014 · 236 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Nabil M. YazgiDirector
- Douglas BeckExecutive Officer
- Sergio TraversaExecutive Officer, Director
- Shreeram AgharkarDirector
- Sandesh SethDirector
- Eliseo O. SalinasExecutive Officer
- Offering amount
- $10.7M
- Amount sold
- $10.7M
- Minimum investment
- $100K
- Sales commissions
- $1.1M
- Placement agents
- Laidlaw & Company (UK) Ltd.
- First sale
- Jun 2014
- Incorporated
- Corporation, Nevada, 2012
- Federal exemptions
- 06b
▶Undisclosed amountofferedJun 2014 · 382 investors · BiotechnologyRule 506(b)
▶Undisclosed amountofferedJun 2014 · 382 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Douglas BeckExecutive Officer
- Sergio TraversaExecutive Officer, Director
- Sandesh SethDirector
- Eliseo O. SalinasExecutive Officer
- Nabil M. YazgiDirector
- Shreeram AgharkarDirector
- First sale
- May 2014
- Incorporated
- Corporation, Nevada, 2012
- Federal exemptions
- 06b
▶$15.1MraisedMay 2014 · 225 investors · BiotechnologyRule 506(b)
▶$15.1MraisedMay 2014 · 225 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Eliseo O. SalinasExecutive Officer
- Douglas BeckExecutive Officer
- Sandesh SethDirector
- Shreeram AgharkarDirector
- Nabil M. YazgiDirector
- Sergio TraversaExecutive Officer, Director
- Offering amount
- $15.1M
- Amount sold
- $15.1M
- Minimum investment
- $100K
- Sales commissions
- $1.8M
- Placement agents
- Laidlaw & Company (UK) Ltd.
- First sale
- May 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Relmada Therapeutics do?
- Relmada is a clinical-stage biopharmaceutical company developing therapies including NDV-01, a sustained-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer, and Sepranolone, a candidate targeting compulsive behaviors via GABAA receptor modulation. Its programs address indications such as bladder cancer and Prader-Willi syndrome.
- Who are Relmada Therapeutics's investors?
- Relmada Therapeutics's investors include BioAdvance, BAM Elevate, Braidwell, Commodore Capital, Janus Henderson Investors, OrbiMed, RA Capital, Venrock and 1 more.
- How much funding has Relmada Therapeutics raised?
- Relmada Therapeutics has disclosed $211.1M raised across 8 of its 10 known rounds.
- Where is Relmada Therapeutics headquartered?
- Relmada Therapeutics is headquartered in New York, US.